Vat-Cit-PAB-Monomethyl Dolastatin 10 is an ADC linker-conjugated drug designed to deliver potent antitumor activity. It achieves this through Monomethyl Dolastatin 10, a potent tubulin inhibitor, connected via the Vat-Cit-PAB ADC linker.
Compound 7, or Raloxifene 6-Monomethyl Ether, is a derivative of Raloxifene that effectively inhibits estrogen receptor α. It also displays the inhibitory effects on MCF-7 cells, with an IC50 of 250 nM and a pIC50 of 6.6.
Raloxifene 4-Monomethyl Ether (Compound 37) is a derivative of Raloxifene which acts as an inhibitor of estrogen receptor α. It effectively suppresses the activity of MCF-7 cells, exhibiting an IC50 value of 1 μM and a pIC50 value of 6.
(E)-3-Hydroxy-5-methoxystilbene possesses inhibitory activity against several Gram-positive bacteria, including isolates of methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium bovis BCG, and avirulent Bacillusanthracis (Sterne strain), among
Monomethyl auristatin E (GMP)是 Monomethyl auristatin E 的 GMP 级别试剂。Monomethyl auristatin E 是一种海兔毒素 10 的合成衍生物,是一种抗有丝分裂剂,通过阻断微管蛋白的聚合来抑制细胞分裂,并且还具有抑制抗体-药物偶联物的活性。